Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02755272 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
A Phase 2 study of Carcinoma Breast Stage IV, sponsored by Fox Chase Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 6
- Study locations
NCT02755272 is a Phase 2 study of Carcinoma Breast Stage IV that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 87 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT02755272, a Phase 2 study of Carcinoma Breast Stage IV, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 6
- Study locations
Study Summary
The main purpose of this study is to see if Pembrolizumab in combination with chemotherapy (carboplatin and gemcitabine) is safe and effective in treating patients with metastatic triple negative breast cancer. Pembrolizumab is a drug which may help the immune system to target and destroy cancer cells. Pembrolizumab has been approved by the FDA for the treatment of advanced melanoma and metastatic non-small cell lung cancer. However, it has not been approved as a treatment for breast cancer.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Gemcitabine
Study Locations (6)
Indiana
- Indiana University - Indianapolis
Missouri
- Washington University in St. Louis - St Louis
New York
- Montefiore Medical Center - The Bronx
North Carolina
- Duke University - Durham
Pennsylvania
- Fox Chase Cancer Center - Philadelphia - Philadelphia
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2016-05-31 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02755272
The ClinicalTrials.gov registry entry for NCT02755272 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma Breast Stage IV appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02755272 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Indiana, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT02755272 about?
NCT02755272 is a clinical study titled "A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer". The main purpose of this study is to see if Pembrolizumab in combination with chemotherapy (carboplatin and gemcitabine) is safe and effective in treating patients with metastatic triple negative breast cancer. Pembrolizumab is a drug which may help the immune system to target and destroy cancer ce...
What is the current status of trial NCT02755272?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2016-05-31. Estimated completion is 2026-05.
What conditions does trial NCT02755272 study?
This clinical trial studies the following conditions: Carcinoma Breast Stage IV.
What interventions are being tested in trial NCT02755272?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02755272?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02755272 being conducted?
This trial has 6 study locations across Indiana, Missouri, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.